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Background: Tumor necrosis factor-α (TNF-α) has been suggested to play a very important role in the
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associations of TNF-α-308 and -238 polymorphisms with HCC risk, but the results remain controversial.
Aim: We conducted this meta-analysis to evaluate the associations between TNF-α-308 and -238
polymorphisms and HCC susceptibility.
Methods: PubMed, Embase, and China National Knowledge Infrastructure electronic databases were
searched for all articles on associations between TNF-α-308 and -238 polymorphisms and HCC risk in
Asians through September 30, 2013. Odds ratios (ORs) and their 95% CIs were calculated to assess the
strength of this association.
Results: A total of 17 case–control studies were identiﬁed in our meta-analysis. For the TNF-α-308 G/A
polymorphism, 14 studies containing 3154 cases and 3767 controls were included. Overall, the frequency
of the A allele was higher in patients with HCC than in the healthy controls (10.2% vs 7.5%), and the
A allele and allele carrier were signiﬁcantly associated with increased risk of HCC in a random effects
model (A vs G: OR ¼ 1.57; 95% CI, 1.22–2.01; P ¼ 0.0004; AA þ AG vs GG: OR ¼ 1.62; 95% CI, 1.18–2.22;
P ¼ 0.003). For the TNF-α-238 polymorphism, 10 research articles were identiﬁed. No association was
found between the TNF-α-238 G/A polymorphism and risk of HCC in any genetic models (P 4 0.05). The
sensitivity analysis further strengthened the overall correlations.
Conclusions: Our meta-analysis proved that the TNF-α-308 G/A polymorphism is associated with
increased susceptibility to HCC. However, the TNF-α-238 G/A polymorphism is not signiﬁcantly
associated with risk of HCC in Asian populations. Further studies with large sample sizes are needed
to conﬁrm these associations among other populations.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer and the third cause of cancer-related mortality worldwide.1
More than 600,000 people die from HCC each year.2 Although
several major risk factors of HCC have been shown to contribute to
hepatocarcinogenesis, the etiology is still unclear. Chronic inﬂam-
mation developing through the action of various inﬂammatory
mediators has been recently identiﬁed as a cofactor in carcino-
genesis.3 Among inﬂammatory mediators, tumor necrosis factor-α
(TNF-α) plays an essential role and has been implicated in
inﬂammation-associated tumors.4Inc. This is an open access article u
e Second Afﬁliated Hospital,
, 548 Bingwen Rd, BingjiangTNF-α, produced by diverse kinds of cells, is 1 of the most
important proinﬂammatory cytokines.5 Researchers have demon-
strated that variation between individual TNF-α concentrations are
attributed to single nucleotide polymorphisms (SNPs) in the TNF
promoter region.6,7 These SNPs have been reported to be associ-
ated with breast cancer,8 gastrointestinal cancer,9 prostate can-
cer,10 lung cancer,11 Graves disease,12 and Alzheimer disease.13
During past years a number of case–control studies have been
conducted to investigate the associations between TNF-α poly-
morphisms and HCC risk in humans, among which TNF-α-308 and
-238 G/A polymorphisms are most highlighted and have been
considered as risk factors for HCC.14,15 But the ﬁndings from
previous studies have been controversial. For example, Qin
et al16 suggested that the TNF-α-308 G/A polymorphism is asso-
ciated with a modest decrease in the risk of developing HCC,
whereas Teixeira et al17 showed that the TNF-α-308 G/A poly-
morphism is signiﬁcantly associated with higher risk of developingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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G/A polymorphism is signiﬁcantly associated with increased risk of
developing HCC, whereas Heneghan et al19 failed to highlight
speciﬁc associations between the 238 G/A polymorphisms tested
and the risk of developing HCC. These discrepancies might be due
to genetic trait differences and different linkage disequilibrium.
Therefore, to derive a more comprehensive estimation of the
associations between TNF-α polymorphisms and HCC risk, we
conducted a meta-analysis to assess the association between
TNF-α-308 and -238 G/A polymorphisms and HCC susceptibility
in Asians.Materials and Methods
Publication search
A computerized search of PubMed, EMBase, and China National
Knowledge Infrastructure electronic databases was conducted to
identify relevant articles published between 2003 and 2013 related
to HCC risk and TNF-α-308 and -238 G/A polymorphisms. The key
words were hepatocellular carcinoma, liver cancer, polymorphism,
variant, and tumor necrosis factor or TNF-α as well as their
combinations. The corresponding Chinese terms were used in
the Chinese database. References of retrieved articles were
checked for other eligible studies. The languages of selected
articles were restricted to English and Chinese. The search was
focused on studies that had been conducted in human beings. Only
full-text articles and the most recent studies were included in our
meta-analysis.Selection criteria
The included studies met the following criteria: a case–control
or cohort association study; conﬁned to Asian populations; include
at least 1 of the 2 SNPs, TNF-α-308, and TNF-α-238; results
expressed as odds ratio (OR) and corresponding 95% CI; and
genotype distribution of control for a certain polymorphism must
be in Hardy-Weinberg equilibrium.213 references initially identified
PubMed (n=103)
Embase (n=78)
CNKI (n=32)
40 full-text articles comprehensively assessed
against inclusion criteria
17 references included in the meta-analysis
10 in English/7 in Chinese
59 
114
Ex
D
W
154 potential records concerning the current topic
Fig. 1. Flow chart of study selection process in our meta-analysis. CNKData extraction
Two investigators independently extracted data and reached a
consensus on all of the items. Any disagreement was resolved by
discussing with the third expert. The following information was
extracted from each article: ﬁrst author, year of publication, total
numbers of case patients and control subjects, and genotyping
information. Furthermore, we examined if matching had been
used and if the genotyping assay had been validated.
Statistical analyses
Statistical analyses were carried out using Review Manager 5.2
(The Cochrane Collaboration, Oxford, United Kingdom). The crude
ORs with 95% CIs were used to measure the associations between
TNF-α polymorphisms and risk of HCC, which were calculated
according to the method of Woolf. The signiﬁcance of the pooled
ORs was determined by the z test, and a P value o 0.05 was
considered statistically signiﬁcant. The allelic model (A vs G) and
genotype genetic models (codominant effects: AA vs GG; dominant
effect: AA þ AG vs GG; and recessive effect: AA vs AG þ GG) were
examined to evaluate the G/A allele with the risk of HCC. Hetero-
geneity of included studies was estimated using Cochran’s Q test
and I2 statistics. P values o 0.1 and I2 o50% were considered to be
statistically signiﬁcant.20 The ﬁxed effects model was used when
the effects were assumed to be homogenous, whereas the random
effects model was used when they were heterogeneous. To assess
if our results were substantially inﬂuenced by the presence of any
individual study, we conducted a sensitivity analysis by system-
atically removing each study and recalculating the signiﬁcance of
the result. Funnel plots were used to evaluate publication bias. All
P values were 2-tailed.Results
Study characteristics
Two hundred thirteen articles were found with our search
criteria. After discarding the duplicate research articles, 154records excluded after duplicate remove
 records excluded after title and abstract review
cluded:
ata not extractable (n=8)
ithout useful data (n=15)
I ¼ China National Knowledge Infrastructure electronic database.
Table I
Main characteristic and genotype distributions of studies included in the meta-
analysis.
First author Year Country Total Genotype frequencies
(GG/AG/AA)
Cases Controls Cases Controls
TNF-α-308
Heneghan 2003 China 98 172 88/10/0 158/13/1
Wang 2003 Japan 125 204 109/15/1 179/23/2
Ho 2004 China 74 289 37/34/3 225/62/2
Chen 2005 China 572 381 468/95/9 311/67/3
Migita 2005 Japan 48 188 47/1/0 183/5/0
Kummee 2007 Thailand 50 150 42/6/2 123/15/12
Jeng 2007 China 108 108 80/28/0 100/8/0
Sakamoto 2008 Japan 209 275 205/4/0 270/5/0
Song 2009 China 81 78 53/28/0 66/12/0
Jeng 2009 China 200 200 149/51/0 188/12/0
Yang 2012 China 772 852 619/145/8 683/160/9
Wang CK 2012 China 620 625 496/118/6 510/108/7
Shi 2012 China 73 116 51/20/2 84/30/2
Wang 2012 China 124 129 96/28/0 114/15/0
TNF-α-238
Heneghan 2003 China 98 172 96/2/0 168/4/0
Wang 2003 Japan 125 204 111/13/1 178/24/2
Huang 2007 China 100 150 88/12/0 143/7/0
Kummee 2007 Thailand 50 150 44/5/1 96/4/50
Jeng 2007 China 108 108 102/6/0 106/2/0
Jeng 2009 China 200 200 194/6/0 198/2/0
Jung 2009 Korea 227 365 193/34/0 336/28/1
Wang 2010 China 230 513 209/20/1 455/57/1
Chen 2011 China 126 126 120/6/0 115/11/0
Wang 2012 China 124 129 117/7/0 125/4/0
TNF-α¼ tumor necrosis factor-α.
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abstract review, 40 full-text articles were preliminarily identiﬁed
for further detailed evaluation. Overall, the initial search with the
key words and the subject terms identiﬁed 17 articles (7 in Chinese
and 10 in English) that met the inclusion criteria and were eligible
for review. The study selection process is shown in Figure 1.
All 17 studies were identiﬁed to evaluate the relationship
between the TNF-α-308 and -238 polymorphisms and risk for
HCC. For the TNF-α-308 polymorphism, 14 relevant studies (4 in
Chinese21–24 and 10 in English19,25–33) with a total of 3154 cases
and 3767 controls were included; for the TNF-α-238 polymor-
phism, 10 research articles (4 in Chinese22,34–36 and 6 in
English19,22,25,29,30,32) were identiﬁed, including 1388 cases and
2117 controls. Characteristics of the included studies are shown in
Table I. All the studies were conducted in persons of Asian descent.
Furthermore, the genotype distributions among the control sub-
jects of all studies were consistent with Hardy-Weinberg
equilibrium.Association between the TNF-α-308 G/A polymorphism and HCC
The main results of meta-analysis of the association between
the TNF-α-308 G/A polymorphism and HCC risk are shown inTable II
Results of pooled odds ratios (ORs) in this meta-analysis.
Genotype Tumor necrosis factor-α-308
OR (95% CI) P Pheterogen
A vs G 1.57 (1.22– 2.01) 0.0004 0.0002
AA vs GG 1.15 (0.70–1.89) 0.57 0.38/7
AA þ AG vs GG 1.62 (1.18–2.22) 0.003 o0.000
AA vs AG þ GG 1.12 (0.68–1.84) 0.65 0.55/0Table II. Overall, the frequency of the A allele is higher in patients
with HCC than in healthy controls (10.2% vs 7.5%). As shown in
Figures 2 and 3, our results showed that there was a signiﬁcant
association between the TNF-α-308 G/A polymorphism and
increased risk of HCC under allelic and dominant effects (A vs G:
OR ¼ 1.57; 95% CI, 1.22–2.01; P ¼ 0.0004; AA þ AG vs GG: OR ¼
1.62; 95% CI, 1.18–2.22; P ¼ 0.003) in a random-effects model,
indicating that being an A carrier may be a risk factor for
developing HCC among Asians. However, under codominant
effects and recessive effects, no signiﬁcant associations were found
(AA vs GG: OR ¼ 1.15; 95% CI, 0.70–1.89; P ¼ 0.57; AA vs AG þ GG:
OR ¼ 1.12; 95% CI, 0.68–1.84; P ¼ 0.65) in a ﬁxed model.
Association between the TNF-α-238 G/A polymorphism and HCC
Table II shows the OR for HCC of TNF-α-238 G/A polymorphism
with the variant genotypes. The heterogeneity between studies
was signiﬁcant and a random-effects model was employed. As
shown in Figures 4 and 5, no signiﬁcant associations were found
in any genotypes (A vs G: OR ¼ 1.06; 95% CI, 0.59–1.92; P ¼ 0.85;
AA vs GG: OR ¼ 0.40; 95% CI, 0.05–2.92; P ¼ 0.36; AA þ AG vs GG:
OR ¼ 1.13; 95% CI, 0.68–1.89; P ¼ 0.64; AA vs AG þ GG: OR ¼
0.39; 95% CI, 0.05–3.02; P ¼ 0.37). This demonstrated that this
polymorphism was not associated with HCC risk.
Sensitivity analysis
The inﬂuence of a single study on the overall meta-analysis
estimate was investigated by omitting 1 study at a time, and the
omission of any study made no signiﬁcant difference, indicating
that our results were statistically reliable.
Publication bias
The shape of the funnel plots was symmetrical, suggesting that
there was no evidence of publication bias among these studies.
Figure 6 displayed funnel plots for the associations between the
TNF-α-308 polymorphism and HCC. The statistical results still did
not show publication bias.Discussion
Carcinogenesis of HCC is a complex process. The risk factors
include chronic infection of hepatitis B virus (HBV) or hepatitis C
virus (HCV) infection, carcinogen exposure, excessive alcohol
consumption, and a variety of genetic factors.37 During recent
decades, inﬂammation has been considered an important factor
involved in carcinogenesis. TNF-α, the most crucial inﬂammatory
cytokine, plays a very important role in inﬂammation and in the
pathogenesis of cancer.38 Studies have demonstrated that TNF-α
was not only involved in the pathogenesis of both hepatitis and
liver cirrhosis,39,40 but also involved in the development of
HCC.41,42 Moreover, TNF-α-308 and -238 polymorphisms have
been reported to be related to risk of HCC because the G/ATumor necrosis factor-α-238
eity/I2 OR (95% CI) P Pheterogeneity/I2
/67% 1.06 (0.59– 1.92) 0.85 o0.00001/78%
% 0.40 (0.05–2.92) 0.36 0.06/59%
01/77% 1.13 (0.68–1.89) 0.64 0.001/67%
% 0.39 (0.05–3.02) 0.37 0.05/61%
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Fig. 2. Forest plot of the association between A allele and hepatocellular carcinoma according to tumor necrosis factor-α-308 polymorphism in an Asian population. M-H ¼
xxxxxxxx.
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production. However the results were inconsistent due to the
rather small size and uniﬁed ethnicity. To provide further inves-
tigation into these controversial points, our meta-analysis was
conducted to achieve a more reliable and comprehensive
conclusion.
We investigated the association between TNF-α-308 and -238
polymorphisms and risk of HCC. A total of 17 studies were
included, 14 for the TNF-α-308 polymorphism and 10 for the
TNF-α-238 polymorphism. The results showed that the variant
genotypes AA/AG of TNF-α-308 G/A were associated with a
signiﬁcantly increased HCC risk when compared with the GG
genotype. Our result is consistent with a previous meta-
analysis.43 However this association was limited to Asian popula-
tions. For the TNF-α-238 G/A polymorphism, no association was
found among Asian people. This result was consistent with Zhou
et al43 and Yang et al,44 but not consistent with Wei et al45 and
Cheng et al.46 In this study, heterogeneity was found for TNF-α-308
and -238 polymorphisms, so a random-effects model was selected
and sensitivity analysis was performed. By removing each study
from our meta-analysis each time and rerunning the model toStudy or Subgroup
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Fig. 3. Forest plot of the association between A carriers (AA þ AG) and hepatocellular car
using random-effect model in an Asian population. AA þ GA, AA, and GA genotypes of TN
xxxxxxxx.determine the effect on each overall estimate, we found quite little
change. This conﬁrmed the stability of our results.
Previous studies found that circulating TNF-α levels were
elevated in patients with HCC.47,48 It is reasonable to speculate
that the high circulating TNF-α levels found in patients with HCC
may be attributed to its SNPs. TNF-α may stimulate the release of
other inﬂammatory cytokines and also induce the production of
other ﬁbrogenic factors, such as tumor growth factor-β, interleu-
kin-1, and interleukin-6,49 which can cause or aggravate liver
damage.6 Because HCC mostly occurs in Asia where HBV and
HCV infections are endemic, the association between TNF-α-308
and -238 G/A polymorphisms and HCC are very important to
identify persons in Asia at greater risk of developing HCC. Our
meta-analysis was only conducted among an Asian population.
Furthermore, the majority of HCCs are related to HBV and HCV
infection, but most studies did not provide the number of patients
with HBV or HCV infection, number of controls with HBV/HCV
infection, or the number of patients with HHC. This suggests that
clarifying the independent role of each polymorphism on HBV,
HCV, and HCC is quite necessary and might explain the discrep-
ancies with other studies. Moreover, a previous meta-analysis with8 [0.55, 3.01]
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Q. Hu et al. / Current Therapeutic Research 76 (2014) 70–7574relatively small sample size may have had insufﬁcient statistical
power to detect a slight effect or may have generated a ﬂuctuated
risk estimate.
Several limitations exist in our meta-analysis. First, environmental
and genetic factors, such as HBV and HCV infection, should be
considered because HCC is a multifactorial disease. Second, some
other single-nucleotide polymorphisms of cytokines should be iden-
tiﬁed to determine the interacting functions. Third, there was
signiﬁcant heterogeneity among the studies in overall comparison
models. According to the problems we addressed, further studies are
needed to detect the independent role of each polymorphism.SE(log[OR])0
0.5
1
1.5
0.01 0.1 1 10 100
OR
Fig. 6. Funnel plots analysis to detect publication bias of this meta-analysis. Each
point represents an independent study for the indicated association.Conclusions
Our meta-analysis suggests that the TNF-α-308 polymor-
phism is associated with risk of HCC, although a signiﬁcant
association was not found between the TNF-α-238 polymor-
phism and HCC. Larger and more rigorous analytical studies are
required to evaluate gene–environment interactions and to
clarify the interaction between the TNF-α polymorphism and
HBV infection status.Acknowledgments
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